Has anyone dealt with telehealth provider directory?

VendorMark said:

Denials are usually procedural rather than clinical, and the order that works reflects that.

VendorMark said:

...compounded vs brand cost and coverage...

This debate comes up weekly and I think both sides have valid points:

Pro-brand: FDA-approved, manufacturing standards guaranteed, clinical trial data directly applicable

Pro-compounded: 10x cost savings, same active molecule, independent testing available, accessibility

My position: if you can afford brand or have insurance coverage, that's the gold standard. If not, properly tested compounded from a 503B pharmacy is a reasonable alternative. Neither side should shame the other.

VendorMark said:

Denials are usually procedural rather than clinical, and the order that works reflects that.

This is where I part company with the consensus forming above. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

DanielChem_CHI said:

The affordability discussion here usually stops at individual tactics.

My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.

CarlaRPh_TPA said:

VendorMark said: ...compounded vs brand cost and coverage...

Can confirm. Same sequence, different timescale. I had assumed I was the exception until I read this.